Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors

Varnier, Romain; Puszkiel, Alicja; Tod, Michel; Calattini, Sara; Payen, Léa; Lopez, Jonathan; Guitton, Jérôme; Schwiertz, Vérane; Fontaine, Juliette; Péron, Julien; Maillet, Denis; Tartas, Sophie; Bonnin, Nathalie; Colomban, Olivier; Augu-Denechere, Diane; You, Benoît

doi:10.1007/s00280-023-04508-9

Cited by 2 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall response rate was 6.3% with a disease control rate of 75%. Intriguingly, the CCA patients displayed the longest median progression-free survival (PFS) of 9.9 months, indicating that the combination of sorafenib and everolimus holds the most significant potential efficacy for CCA treatment amongst the studied cancers [54].…”

Section: Pi3k/pten/akt/mtor Signaling Pathway Inhibitorsmentioning

confidence: 99%

Emerging Therapies in Management of Cholangiocarcinoma

Speckart,

Rasmusen,

Talib

et al. 2024

Cancers

View full text Add to dashboard Cite

Cholangiocarcinoma is a heterogeneous group of biliary tract cancers that has a poor prognosis and globally increasing incidence and mortality. While surgical resection remains the only curative option for the treatment of cholangiocarcinoma, the majority of cancers are unresectable at the time of diagnosis. Additionally, the prognosis of cholangiocarcinoma remains poor even with the current first-line systemic therapy regimens, highlighting the difficulty of treating locally advanced, metastatic, or unresectable cholangiocarcinoma. Through recent developments, targetable oncogenic driver mutations have been identified in the pathogenesis of cholangiocarcinoma, leading to the utilization of molecular targeted therapeutics. In this review, we comprehensively discuss the latest molecular therapeutics for the treatment of cholangiocarcinoma, including emerging immunotherapies, highlighting promising developments and strategies.

show abstract

Section: Pi3k/pten/akt/mtor Signaling Pathway Inhibitorsmentioning

confidence: 99%